# Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

> **NCT03565367** · PHASE1 · COMPLETED · sponsor: **Daniel M. Spielman** · enrollment: 9 (actual)

## Conditions studied

- Malignant Central Nervous System Neoplasm
- Metastatic Malignant Neoplasm in the Central Nervous System

## Interventions

- **OTHER:** Gadolinium
- **DRUG:** Hyperpolarized Carbon C 13 Pyruvate
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Magnetic Resonance Spectroscopic Imaging

## Key facts

- **NCT ID:** NCT03565367
- **Lead sponsor:** Daniel M. Spielman
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-06
- **Primary completion:** 2019-06-20
- **Final completion:** 2019-06-20
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565367, "Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03565367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*